Febrile Neutropenia - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Febrile Neutropenia - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 51-page report is available in PDF from $2000.

Febrile Neutropenia - Pipeline Review, H1 2015


Global Markets Direct’s, ‘Febrile Neutropenia - Pipeline Review, H1 2015’, provides an overview of the Febrile Neutropenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Febrile Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Febrile Neutropenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Febrile Neutropenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Febrile Neutropenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Febrile Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Febrile Neutropenia Overview 7
Therapeutics Development 8
Pipeline Products for Febrile Neutropenia - Overview 8
Pipeline Products for Febrile Neutropenia - Comparative Analysis 9
Febrile Neutropenia - Therapeutics under Development by Companies 10
Febrile Neutropenia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Febrile Neutropenia - Products under Development by Companies 14
Febrile Neutropenia - Companies Involved in Therapeutics Development 15
Apotex, Inc. 15
Biocon Limited 16
Coherus BioSciences, Inc. 17
Pfizer Inc. 18
Richter Gedeon Nyrt. 19
Sandoz International GmbH 20
Teva Pharmaceutical Industries Limited 21
Therapeutic Proteins International, LLC 22
Xenetic Biosciences plc 23
Febrile Neutropenia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(piperacillin sodium + tazobactam sodium) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
filgrastim - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
filgrastim - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
filgrastim (recombinant) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
lipegfilgrastim - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pegfilgrastim - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pegfilgrastim - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
pegfilgrastim - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pegfilgrastim - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
pegfilgrastim - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
pegfilgrastim - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Stimuxen - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Febrile Neutropenia - Recent Pipeline Updates 47
Febrile Neutropenia - Product Development Milestones 48
Featured News & Press Releases 48
Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study 48
Jul 02, 2014: Application for the Additional Indication of Febrile Neutropenia for ZOSYN, an Injectable Antibiotic Combined with ß-Lactamase Inhibitor 48

For more information open Febrile Neutropenia - Pipeline Review, H1 2015.


Original Article: Febrile Neutropenia - Pipeline Review, H1 2015


More From BioPortfolio on "Febrile Neutropenia - Pipeline Review, H1 2015"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...